Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bold Brandicourt Plots Mega Sanofi And Boehringer Animal, Consumer Asset Swap

This article was originally published in Scrip

Executive Summary

Sanofi and Boehringer Ingelheim are in exclusive negotiations to swap parts of their businesses. The deal would involve an exchange of Sanofi's animal health business Merial, which is worth €11.4bn, with Boehringer's consumer healthcare (CHC) business, worth €6.7bn. To make up the difference in value between the two businesses, Boehringer would make a cash payment to Sanofi of €4.7bn.

You may also be interested in...



136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure

The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.

AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss

During third-quarter earnings report, Brandicourt said he remains confident about Sanofi's prospects in oncology despite losing the takeover fight for Medivation, although he didn't rule out another mid-sized bolt-on attempt if the opportunity arose.

Related Content

Topics

UsernamePublicRestriction

Register

SC063984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel